Dec 9, 2024 · Brilliantly written and explained in very easy language – thank you. I have just become a carer for a family member with dementia and your forthright and considerate information has been most helpful in understanding what may lay ahead.

Lecanemab (lek-an-e-mab), also called LEQEMBI®, is a drug treatment for Alzheimer’s disease. It is made by the drug company Eisai. It has been licensed for prescription in the UK for people with a confirmed diagnosis of:

Jun 10, 2022 · PET scans detect specific molecules in the brain. They are more commonly used in research than for diagnosis. By injecting or swallowing safe radioactive dyes which bind to molecules in the brain, the scanner can produce an image of where the target molecules are by detecting the dyes.

Nov 9, 2023 · A new year has arrived. For some, this is the time of year to reflect on both ourselves, and the loved ones we’ve recently spent time with. If you spent time with family and friends, especially those you may not have seen for a while, you might have noticed changes in them that weren’t there before.

Amyloid is a protein which builds up in the brain in Alzheimer’s disease. The discovery of amyloid in Alzheimer’s disease was made possible by scientists who worked with families who had a strong family history of dementia in their 40s and 50s going back generations.

Risk factors for dementia we can't control. These are called ‘non-modifiable’ risk factors because we cannot ‘modify’ or change them. Here we explain how each non-modifiable risk factor relates to our likelihood of getting dementia.

Alzheimer's Research UK are the UK's leading Alzheimer's research charity aiming to find a cure for dementia. Together we have the power to make breakthroughs possible.

Growing evidence suggests that a healthy, balanced diet may reduce our risk of dementia. This is because what we eat affects our overall health and can contribute to the development of conditions like heart disease or obesity, which increase our likelihood of getting dementia.

Today 23 rd October 2024, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has licensed a second drug that can slow down Alzheimer’s disease, called donanemab. This means that the MHRA have decided that donanemab is safe and effective to offer to people with Alzheimer’s in Great Britain. However donanemab has been provisionally rejected by the NHS’s decision-makers NICE.

In our body, there are billions of nerve cells which send messages to each other. These messages help us to move, think, and remember. In Alzheimer’s disease and dementia with Lewy bodies, nerve cells become damaged and lose their ability to send messages.